Establishment and validation of a 28-day clinical outcome prediction model for acute promyelocytic leukemia based on an early platelet-coagulation factor combined transfusion strategy.

Shuaikui Zheng, Xiaocai Zheng, Zhanwei Li

Abstract read

In one paragraph

Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shuaikui ZhengDepartment of Blood Transfusion, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University Zhengzhou 450000, Henan, China.

Xiaocai ZhengDepartment of Gastroenterology and Hemorrhoid and Fistula Surgery, Jiaxian People's Hospital Jia County, Pingdingshan 467100, Henan, China.

Zhanwei LiDepartment of Blood Transfusion, The First Affiliated Hospital of Henan University of Science and Technology Luoyang 471000, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early mortality in acute promyelocytic leukemia (APL) remains a major challenge, and the Sanz risk stratification has limited predictive value. This retrospective multicenter study aimed to establish and externally validate a 28-day mortality risk prediction nomogram integrating an early platelet-coagulation factor (PLT-CF) combined transfusion strategy. A total of 631 newly diagnosed APL patients from two tertiary hospitals (2019-2024) were divided into a training cohort (n = 429) and an external validation cohort (n = 202). Independent predictors were identified by multivariate Cox regression and incorporated into a nomogram. Model performance was assessed by time-dependent ROC curves, calibration, decision curve analysis (DCA), and Kaplan-Meier survival analysis, with comparison against the Sanz system. The 28-day mortality rate was 19.02% (120/631). Six independent predictors were identified: decreased fibrinogen (HR = 0.254, P < 0.001), decreased hemoglobin (HR = 0.989, P = 0.034), age ≥ 45 years (HR = 2.037, P = 0.003), Charlson Comorbidity Index score 1-3 (HR = 1.877, P = 0.005), white blood cell count > 10 × 10

Indexed as

Acute promyelocytic leukemiaearly mortalityexternal validationnomogramplatelet-coagulation factors combined transfusionpredictive model

Identifiers

PMID42266758

DOI10.62347/AUHX4651

PMCPMC13243677

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.